Selektive Reduktion von Cysteinresten in Il-17-Antikörpern

Details

Veröffentlichungs-Nr.

EP4732845

Anmeldetag

21. Dezember 2015

Veröffentlichung

29. April 2026

Rechtsraum

EP

IPC

C07K16/24, A61K39/395A61K39/395(NOVARTIS AG et al.)

Abstract

The present disclosure relates to methods for selectively reducing CysL97 in a preparation of IL-17 antibodies or antigen binding fragments thereof (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g, purified preparations of secukinumab, wherein the level of intact IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 90%, as measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS), and wherein the level of activity of IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 92%, as measured by cation exchange chromatograph (CEX).

Anmelder

Firma

Novartis AG

Land

🇨🇭 Schweiz

Fachgebiete